Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,663 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.
Caocci G, Martino B, Greco M, Abruzzese E, Trawinska MM, Lai S, Ragatzu P, Galimberti S, Baratè C, Mulas O, Labate C, Littera R, Carcassi C, Gambacorti Passerini C, La Nasa G. Caocci G, et al. Among authors: greco m. Exp Hematol. 2015 Dec;43(12):1015-1018.e1. doi: 10.1016/j.exphem.2015.08.004. Epub 2015 Aug 22. Exp Hematol. 2015. PMID: 26306453 Free article. Clinical Trial.
Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Caocci G, Vacca A, Ledda A, Murgia F, Piras E, Greco M, Arras M, Atzeni S, Littera R, La Nasa G. Caocci G, et al. Among authors: greco m. Biol Blood Marrow Transplant. 2012 Apr;18(4):652-4. doi: 10.1016/j.bbmt.2011.12.587. Epub 2012 Jan 9. Biol Blood Marrow Transplant. 2012. PMID: 22240733 Free article. No abstract available.
Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco M, Orrù S, Orrù N, Floris A, Carcassi C. La Nasa G, et al. Among authors: greco m. Exp Hematol. 2013 May;41(5):424-31. doi: 10.1016/j.exphem.2013.01.008. Epub 2013 Feb 1. Exp Hematol. 2013. PMID: 23380384 Free article.
Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A, Di Raimondo F, La Nasa G, Romano A, Borra A, Greco M. Gallamini A, et al. Among authors: greco m. Immunol Lett. 2013 Sep-Oct;155(1-2):56-9. doi: 10.1016/j.imlet.2013.09.011. Epub 2013 Oct 16. Immunol Lett. 2013. PMID: 24140162 Review.
Immunological deregulation in classic hodgkin lymphoma.
Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, La Nasa G. Romano A, et al. Among authors: greco m. Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014039. doi: 10.4084/MJHID.2014.039. eCollection 2014. Mediterr J Hematol Infect Dis. 2014. PMID: 24959336 Free PMC article. Review.
The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.
La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella R, Martino M, Romano A, Di Raimondo F, Gallamini A, Carcassi C, Caocci G. La Nasa G, et al. Among authors: greco m. J Hematol Oncol. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4. J Hematol Oncol. 2016. PMID: 26983546 Free PMC article.
1,663 results